Andrew Roberts is the Head of Clinical Translation at the Walter & Eliza Hall Institute, a clinical haematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Haematology Research and Education Lead for the Victorian Comprehensive Cancer Centre (VCCC), and the Metcalf Chair of Leukaemia Research at the University of Melbourne.

His major research interests are the development of new treatments for leukaemia, lymphoma and myeloma through translational and clinical research. He has been an academic leader in the clinical development of the novel targeted anti-cancer drug, venetoclax, from the research laboratory through clinical trials to FDA & TGA approval for use in treatment of selected leukaemia patients.

An experienced haematologist and laboratory researcher, Andrew champions the role of research in continuing to improve the care that we provide to people with blood cancers. Joint appointments with the Walter & Eliza Hall Institute and the University of Melbourne ensure that clinical care provided by the integrated clinical haematology department of Royal Melbourne Hospital and Peter MacCallum Cancer Centre is linked to the precinct’s world leading research.